Farmacología y Toxicología
Departamento
Centro de Investigación Cooperativa en Biomateriales
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Cooperativa en Biomateriales (9)
2023
-
Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)
Frontiers in Pharmacology
-
Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
Frontiers in Pharmacology, Vol. 14
2020
-
Na+ controls hypoxic signalling by the mitochondrial respiratory chain
Nature, Vol. 586, Núm. 7828, pp. 287-291
-
Probiotic Bifidobacterium breve prevents DOCA-salt hypertension
FASEB Journal, Vol. 34, Núm. 10, pp. 13626-13640
-
Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation
Nature Immunology, Vol. 21, Núm. 2, pp. 135-144
2018
-
HIV transgene expression impairs K+ channel function in the pulmonary vasculature
American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 315, Núm. 5, pp. L711-L723
-
Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage
Redox Biology, Vol. 15, pp. 143-158
-
Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome
Scientific Reports, Vol. 8, Núm. 1
2015
-
Imaging the role of toll-like receptor 4 on cell proliferation and inflammation after cerebral ischemia by positron emission tomography
Journal of Cerebral Blood Flow and Metabolism, Vol. 36, Núm. 4, pp. 702-708